2型糖尿病与骨质疏松症:优化管理指南
本文系统检索截至2017年3月的人体研究,综述2型糖尿病(T2D)患者的骨质疏松与骨折风险、降糖治疗对骨代谢的影响及抗骨质疏松药物对T2D的影响,并按美国内科医师学会(American College of Physicians)分级系统给出个体化优化管理推荐。
要点
- 健康饮食与体育锻炼对T2D和骨质疏松症的防治均非常重要。
- T2D合并骨质疏松患者降糖可优先选用二甲双胍、磺脲类、二肽基肽酶-4抑制剂和胰高血糖素样肽-1受体激动剂,但应避免严格降糖目标以防低血糖、跌倒和骨折。
- 噻唑烷二酮类和卡格列净应避免使用,其他钠-葡萄糖协同转运蛋白2抑制剂为验证较少的选项;骨质疏松的治疗与监测应继续,不因T2D而重大调整。
核心结论
- T2D与骨质疏松症常因老龄化而共存,T2D患者骨折风险升高,应按科学证据进行优化管理。
研究设计与样本
- 在PubMed、Cochrane和EMBASE三个电子数据库系统检索截至2017年3月的人体研究,推荐采用美国内科医师学会(American College of Physicians)分级系统。
主要发现
- 健康饮食和体育锻炼对T2D和骨质疏松症的预防和治疗均非常重要。
- 二甲双胍、磺脲类、二肽基肽酶-4抑制剂和胰高血糖素样肽-1受体激动剂应优先用于这些患者的T2D治疗,但应避免严格目标以防低血糖、跌倒和骨折。
- 胰岛素应谨慎使用并采取仔细措施避免低血糖。
- 噻唑烷二酮类和卡格列净应避免使用,其他钠-葡萄糖协同转运蛋白2抑制剂为验证较少的选项。
- 住院T2D合并骨折患者首选胰岛素治疗以达到血糖控制。
关键数值与推荐
- T2D合并骨质疏松患者降糖优先选用二甲双胍、磺脲类、二肽基肽酶-4抑制剂和胰高血糖素样肽-1受体激动剂。
- 应避免严格降糖目标以防低血糖、跌倒和骨折。
- 噻唑烷二酮类和卡格列净应避免使用,其他钠-葡萄糖协同转运蛋白2抑制剂为验证较少的选项。
- 住院T2D合并骨折患者首选胰岛素治疗。
- 骨质疏松的治疗和监测应继续,不因T2D而重大调整。
临床怎么用
- 对T2D合并骨质疏松患者,优先选用二甲双胍、磺脲类、二肽基肽酶-4抑制剂和胰高血糖素样肽-1受体激动剂,避免严格降糖目标。
- 胰岛素应谨慎使用并仔细避免低血糖,噻唑烷二酮类和卡格列净应避免使用。
- 住院T2D合并骨折患者首选胰岛素治疗。
- 骨质疏松的治疗和监测应继续,不因T2D而重大调整。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Both type 2 diabetes (T2D) and osteoporosis are affected by aging and quite often coexist. Furthermore, the fracture risk in patients with T2D is increased. The aim of this article is to review updated information on osteoporosis and fracture risk in patients with T2D, to discuss the effects of diabetes treatment on bone metabolism, as well as the effect of antiosteoporotic medications on the incidence and control of T2D, and to provide a personalized guide to the optimal management. EVIDENCE ACQUISITION: A systematic literature search for human studies was conducted in three electronic databases (PubMed, Cochrane, and EMBASE) until March 2017. Regarding recommendations, we adopted the grading system introduced by the American College of Physicians. EVIDENCE SYNTHESIS: The results are presented in systematic tables. Healthy diet and physical exercise are very important for the prevention and treatment of both entities. Metformin, sulfonylureas, dipeptidyl peptidase-4 inhibitors, and glucagon-like peptide-1 receptor agonists should be preferred for the treatment of T2D in these patients, whereas strict targets should be avoided for the fear of hypoglycemia, falls, and fractures. Insulin should be used with caution and with careful measures to avoid hypoglycemia. Thiazolidinediones and canagliflozin should be avoided, whereas other sodium-dependent glucose transporter 2 inhibitors are less well-validated options. Insulin therapy is the preferred method for achieving glycemic control in hospitalized patients with T2D and fractures. The treatment and monitoring of osteoporosis should be continued without important amendments because of the presence of T2D. CONCLUSIONS: Patients with coexisting T2D and osteoporosis should be managed in an optimal way according to scientific evidence.
引用
- Paschou SA, Dede AD, Anagnostis PG, et al. Type 2 Diabetes and Osteoporosis: A Guide to Optimal Management. J Clin Endocrinol Metab. 2017. PMID: 28938433. doi:10.1210/jc.2017-00042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。